Theragenics Corporation : Theragenics Announces Final Results of Dutch Auction Tender Offer
07/17/2012| 04:50pm US/Eastern
Theragenics Corporation® (NYSE: TGX), a medical device
company serving the surgical products and prostate cancer treatment
markets, today announced the final results of its modified "Dutch
Auction" tender offer to purchase up to $10 million of its common stock,
which expired at 5:00 p.m., New York time, on July 11, 2012.
In accordance with the terms and conditions of the offer, Theragenics
has accepted for purchase 4,761,904 shares of its common stock at a
purchase price of $2.10 per share, for a total cost of approximately $10
million, excluding fees and expenses related to the tender offer. The
4,761,904 shares accepted for purchase in the tender offer represent
approximately 13.7% of Theragenics' currently outstanding common stock.
Based on the final count by the depositary, a total of 7,077,229 shares
of Theragenics' common stock were tendered properly and not withdrawn
properly at or below the final purchase price of $2.10 per share.
After giving effect to the priority purchase of all shares validly
tendered by "odd lot" holders, the depositary has informed Theragenics
that stockholders who tendered properly and did not withdraw properly
shares of common stock in the offer at or below $2.10 per share will
have approximately 67% of their tendered shares purchased by Theragenics.
The depositary will promptly issue payment for the shares accepted for
purchase in accordance with the terms and conditions of the offer.
Shares tendered and not accepted for purchase will be returned promptly
to stockholders by the depositary.
As a result of the completion of the offer, Theragenics has
approximately 29,968,000 shares outstanding.
Stockholders who have questions may call Georgeson Securities
Corporation, the dealer-manager for the offer, at (800) 445-1790, or
Georgeson Inc., the information agent for the offer, at (877) 278-4751.
Statements included in this press release which are not historical
facts are forward looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995 and
the Securities Exchange Act of 1934. Such forward looking statements are
made based upon management's expectations and beliefs concerning future
events impacting the Company and therefore involve a number of
uncertainties and risks, including, but not limited to, those described
in the Company's Annual Report on Form 10-K for 2011 and other filings
with the Securities and Exchange Commission. Therefore, the actual
results of operations or financial condition of the Company could differ
materially from those expressed or implied in such forward-looking
Frank Tarallo, 800-998-8479 - 770-271-0233
Lisa Rassel, 800-998-8479 - 770-271-0233
of Investor Relations
© Business Wire 2012